The present invention discloses a novel anti-diabetic composition extracted from fenugreek seeds. The same comprises a furostanolic-saponin-rich fraction (>70%) with approximately 30% protodioscin as one of the bioactive components. Pre-clinical studies in rats indicated significant glucose lowering effect of the fraction (31.5%) as compared to control after two weeks of oral treatment. Clinical studies in human volunteers indicated suitability of a dosage form of 500 mg given once or twice dail...

An antidiabetic (type II diabetes) oral pharmaceutical form containing an active principle A which is a biguanide such as metformin and at least another active principle B capable of being easily swallowed in a single daily dose.The antidiabetic active principle B may be glibenclamide pioglitazone hydrochloride rosiglitazone maleate nateglinide glipizide or glimepiride.A capsule having a core based on metformin and a coating film applied on the core which enables prolonged release in vivo of met...